Cognition
Pep-Pedia reports cognition interest; exact-analogue clinical benefit remains unverified.2
Mind & sleep
NA Semax Amidate
Terminally modified Semax analogue
No FDA-approved product identified for this exact research entry in the targeted review.
What does it do?
NA Semax Amidate is marketed as N-acetyl Semax with a C-terminal amide. Parent Semax findings do not establish this exact analogue’s effects or improved delivery.
Amino-acid sequence
An exact sequence has not been verified for this formulation.
Reference identity · not independently confirmed7
Length7 amino acids
Molecular weight · Da1,007.16 Da
How long does it stay in the body?
Pharmacokinetics · How quickly the compound clears.
Half-lifeHuman half-life not verified2
No numerical human elimination estimate was verified for the exact material in this review.
There is not enough numerical information in the checked sources to show a clearance curve.
What to expect
Study outcomes
Exact analogue has an evidence gap
No controlled human trial of this exact modified analogue was verified.1
Doses by goal
These are reported practices from secondary sources, not validated dosing recommendations.
Route
Scroll to compare all columns →
| Goal | Dose | Frequency | Route | Duration | Source |
|---|---|---|---|---|---|
| Cognitive enhancement | 600μg | 1x daily | IntranasalNasal spray | 10-30 days | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses. Source tabs Nasal | |||||
| Mental fatigue resistance | 800μg | 1x daily | IntranasalNasal spray | 10-30 days | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses. Source tabs Nasal | |||||
| Memory enhancement | 600μg | 2x daily | IntranasalNasal spray | 10-30 days | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses. Source tabs Nasal | |||||
| Neuroprotection | 1200μg | 1x daily | IntranasalNasal spray | 10-30 days | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses. Source tabs Nasal | |||||
| Research protocol | 200μg | 1x daily | SubQ | 7-21 days | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses. Source tabs Injectable | |||||
| Neuroprotection study | 400μg | 1x daily | SubQ | 7-21 days | 7 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses. Source tabs Injectable | |||||
No protocols match these filters.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Nasal
- Use period
- 10-30 days
- Break
- Equal length break
Reported timing
Morning or early afternoon
Injectable
- Use period
- 7-21 days
- Break
- Equal break
Reported timing
Morning preferred
Side effects & safety
Evidence limitation
Comparative human potency and exposure are unknown.
1Evidence limitation
Parent Semax tolerability cannot be assumed to cover this modified compound.
1Local/systemic effects
Nasal irritation/bleeding, headache, insomnia, allergy or injection infection; pregnancy safety unknown.
Quality and route
Congestion changes absorption; sterile preparation does not establish efficacy/safety.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
7 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Modafinil
Caution reportedPossible overstimulation.7
Reference report · Pep-Pedia label: Monitor CombinationBlood-pressure medicines
Caution reportedPossible vascular effects.7
Reference report · Evidence context: Monitor combinationMAO inhibitors
Avoidance reportedUncharacterized neurotransmitter interaction.7
Reference report · Pep-Pedia label: Avoid CombinationNA Selank amidate
Unverified pairingUntested cognitive/anxiety pairing.7
Reference report · Pep-Pedia label: SynergisticBPC-157
Unverified pairingSafety unestablished.7
Reference report · Pep-Pedia label: CompatibleLion's mane
Unverified pairingNeurotrophic hypothesis.7
Reference report · Pep-Pedia label: CompatibleOther medicines or peptides
Not establishedNo exact-product human interaction study was verified; lack of evidence is not evidence of safety.2
Research contextNo matching interactions. Try another name or filter.
Reconstitution
No product-specific preparation or stability instruction was verified. A dilution calculation does not establish suitability for injection.2
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Nasal
Pep-Pedia distinguishes preservative-free saline from BAC water for nasal preparations.
- Solvents mentioned
- Sterile saline / Bacteriostatic water — source alternative
- Reported parameters
- Source-reported intervals: saline, 24–48 hours; BAC water, 28 days; both refrigerated. · It warns that benzyl alcohol in BAC water may irritate nasal tissue.
The source also suggests frozen aliquots; it does not establish validated stability or container compatibility for every nasal formulation.
Injectable
The injectable steps name BAC water and refrigeration.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Reported interval: 28 days.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearanceWhite, fluffy powderReported appearanceClear solutionReported concernDiscolored powder
7Available forms
No verified packaging examples included.
Packaging examples, not a market survey. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Pep-Pedia reports these handling limits after mixing. They are not validated stability or sterility limits for your vial.
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Evidence limits
View findings →No controlled human trial of this exact modified analogue was verified.1
Unverified. Human administration evidence for this exact compound has not been verified. Parent-compound research is not equivalent.
Evidence definitions →Research findings
No human data verifiedSource context
Source's 'proven efficacy' and superior bioavailability language overstates verified derivative-specific evidence. Interaction labels are hypotheses.
Compound identity & other names
NA Semax Amidate is marketed as N-acetyl Semax with a C-terminal amide. Parent Semax findings do not establish this exact analogue’s effects or improved delivery.
No FDA-approved product identified for this exact research entry in the targeted review.
Terminally modified Semax analogue27
Pep-Pedia identity record
7 amino acids · 1,007.16 Da
Asn-Ala-Met-Glu-His-Phe-Pro-Gly-Pro-NH₂Reference description; checked chemical identity takes precedence when available.7
How it may work
Proposed neurotrophic/neurotransmitter pathways; direct nasal brain access and systemic bioavailability require derivative-specific confirmation.7
Exact analogue has an evidence gap
Parent-Semax experiments do not establish that acetylation and amidation preserve benefit, improve brain exposure, or make a safe human product.
1Research areas and evidence gaps
- No controlled human trial of this exact modified analogue was verified.
- A product-specific research-vial quantity was not independently verified in this review.
Additional uses listed by Pep-Pedia
Focus, learning and memory. Source reports attention, fatigue resistance and consolidation; direct clinical evidence limited.7
Neuroprotection and stroke recovery. Parent-compound/experimental extrapolation, not an established derivative indication.7
Delivery research. Nasal/injectable exposure claims require measured PK.7
Community reports Unvalidated
Pep-Pedia discusses cognition and mental fatigue interest.2
Editorial summary, not a measured community survey, clinical protocol or recommendation.
Search coverage and review status
No exact-analogue controlled human trial was verified. Recent parent-Semax cell research is labeled as indirect.
- Checked
- 2026-10-12
- Search
- "N-acetyl" "Semax" "2025" study
- Catalog
- Pep-Pedia ↗ · 4 listed references retained
- Targeted search and selected primary-source checks, not an exhaustive systematic review.
- Preserved bibliography entries marked unreviewed have not had their findings independently verified.
AI-prepared summaries. Independent medical editorial review is pending.
Community poll 10 topics · Pep-Pedia snapshot
Voluntary, unverified reports. These percentages do not measure effectiveness or safety.
Experience
Number of responses to this question: not disclosed.
Duration of use
Number of responses to this question: not disclosed.
Age range
The source hides 1 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Gender
Number of responses to this question: not disclosed.
Primary goal
Number of responses to this question: not disclosed.
Effectiveness
The source hides 4 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Side effects
The source hides 5 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Dosage frequency
The source hides 3 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Would recommend
Number of responses to this question: not disclosed.
How discovered
The source hides 2 additional categories. Their labels and percentages are unavailable.
Number of responses to this question: not disclosed.
Source & limitations
The source displays “661 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.
- Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
- The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
- Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
- Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
- This is a dated snapshot, not a live survey or current recommendation.
References
Original sources and review status. Open a reference to read its summary.
1The Effect of Peptide Semax, an ACTH(4-10) Analogue, on Intracellular Calcium Dynamics in Rat Brain NeuronsAbstract checked
AI-PREPARED SUMMARY
This study used parent Semax in rat brain slices, not N-acetyl Semax amidate. Calcium-signaling observations cannot establish the modified analogue’s effects.
Exact analogue has an evidence gap
Parent-Semax experiments do not establish that acetylation and amidation preserve benefit, improve brain exposure, or make a safe human product.
Additional research · Checked 2026-10-12
2Pep-Pedia: NA Semax AmidateCommunity source checked
AI-PREPARED SUMMARY
Secondary editorial profile and reported practices; not clinical validation.
3Default Mode Network Enhancement (2018)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The reported imaging changes concern parent Semax, not the amidated derivative; an fMRI change alone does not establish better memory.
Reported population / model
24 participants
Reported study details
1% solution intranasal · fMRI monitoring · DMN volume increase
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
4Stroke Recovery and BDNF Enhancement (2018)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Parent Semax studies reportedly linked higher BDNF with motor recovery after stroke; the modified NA-Semax product was not directly tested.
Reported population / model
110 stroke patients
Reported study details
10-day treatment protocol · BDNF level monitoring · Motor function improvement
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
5Gene Expression and Neuroprotection (2014)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Parent Semax altered immune, vascular and injury-response gene expression in rat brain-ischemia models; amidated-product efficacy was not tested.
Reported population / model
Rat model
Reported study details
Genome-wide analysis · 3-24 hour timepoints · 96+ gene expression changes
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
6Cognitive Enhancement in Fatigued Subjects (1996)No study link suppliedPep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports memory accuracy of 71% versus 41% during demanding work conditions with Semax; this is not direct NA-Semax-amidate evidence.
Reported population / model
Human study
Reported study details
250-1000μg intranasal · 24-hour effects · 71% vs 41% memory accuracy
Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified. No study link supplied
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
7Pep-Pedia: NA Semax Amidate — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12